Tartu, Estonia

Kadri Janikson

USPTO Granted Patents = 2 


Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Kadri Janikson

Introduction

Kadri Janikson, an inventive researcher based in Tartu, Estonia, has made significant strides in the field of molecular biology. With two patents to his name, he has contributed to advancements in protein production and gene expression technologies that are crucial for both research and therapeutic applications.

Latest Patents

Janikson's latest inventions focus on viral expression plasmids designed for the production of proteins, antibodies, enzymes, and virus-like particles. His first patent details the incorporation of the Epstein-Barr virus (EBV) FR-element comprised of EBNA1 multimeric binding sites, which facilitates stable maintenance and replication in mouse polyomavirus (PyV) core origin plasmids. This innovative approach is particularly valuable when used in conjunction with the BPV-1 E2 protein and PyV large T-antigen (LT).

In his second patent, Janikson introduces vectors and cell lines that enable extended episomal maintenance replication of hybrid plasmids and the expression of gene products. This invention emphasizes the use of a minichromosome maintenance element (MME) dependent on BPV-1 E2 protein, which showcases a remarkable stability: these plasmids are lost at a mere 6% frequency per generation. His findings also suggest that stable replication of the Polyomavirus core origin plasmids can occur without selection pressure, a critical factor for sustainable gene expression in various cell types.

Career Highlights

Throughout his career, Kadri Janikson has collaborated with prominent biotechnology companies, including Kosagen Cell Factory OÜ and Icosagen Cell Factory OÜ. His work has positioned him as a key player in the biotechnology sector, where his contributions to plasmid technology are revolutionizing the way proteins and antibodies are produced and utilized in scientific research.

Collaborations

Collaboration has been an essential aspect of Janikson's success. He has worked alongside notable colleagues, such as Toomas Silla and Ingrid Tagen, fostering an environment of innovation and shared knowledge that has led to groundbreaking advancements in their field.

Conclusion

Kadri Janikson's innovative contributions through his patents in viral expression systems reflect his dedication to enhancing biotechnological applications. His collaborations and career achievements underscore the importance of teamwork in science, paving the way for future breakthroughs in molecular biology and biotechnology. As he continues to push the boundaries of scientific discovery, Janikson remains a notable figure in the world of inventions and innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…